This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.
Susanna Hegewisch-becker, MD, PhD
Advertisement
Articles by Susanna Hegewisch-becker, MD, PhD
Advertisement
Latest Updated Articles
- UFT/Leucovorin Plus Weekly Irinotecan in Advanced or Metastatic Colorectal Cancer
Published: October 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
2
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
3
What Were The Most Impactful GU Oncology Data From ESMO 2025?
4
FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications
5
